ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)

With the exception of VEGF-targeted agents, the overall risk of infection associated with the reviewed therapies seems to be low.